Fenleuton (trade name Lofrin) is a drug that acts as a 5-lipoxygenase inhibitor and inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. It has been studied for potential use in veterinary medicine to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD) in horses.[2]

Fenleuton
Clinical data
Trade namesLofrin
ATC code
  • none
Identifiers
  • 1-{4-[3-(4-Fluorophenoxy)phenyl]-3-butyn-2-yl}-1-hydroxyurea
CAS Number
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H15FN2O3
Molar mass314.316 g·mol−1
3D model (JSmol)
  • CC(C#Cc1cccc(c1)Oc2ccc(cc2)F)N(C(=O)N)O
  • InChI=InChI=1S/C17H15FN2O3/c1-12(20(22)17(19)21)5-6-13-3-2-4-16(11-13)23-15-9-7-14(18)8-10-15/h2-4,7-12,22H,1H3,(H2,19,21)
  • Key:MWXPQCKCKPYBDR-UHFFFAOYSA-N[1]

References

edit
  1. ^ "1-{4-[3-(4-Fluorophenoxy)phenyl]-3-butyn-2-yl}-1-hydroxyurea". chemspider.com. Retrieved 24 December 2015.
  2. ^ Marr KA, Lees P, Page CP, Cunningham FM (1998). "Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease". J Vet Pharmacol Ther. 21 (3): 241–246. doi:10.1046/j.1365-2885.1998.00127.x. PMID 9673966.